@ACTREC_TMC@nvpatkar@JCO_ASCO Hearty congratulations to the team ! Once again provides evidence that biology-driven precision can redefine standard therapy💐💐
#Liquidbiopsy on the road: truth or illusion?
A 65-year-old with colon cancer gets a blood test 200 km away. The ctDNA report comes back negative
Watch the full video here 👉 https://t.co/KLmch2z0PU
Please like , subscribe and share
We are proud to welcome and congratulate our new CoP Subcommittee leaders across Social Media, Research, Community/Rural, Global, AI and more. Your leadership will shape how we connect, advocate, and grow together. @ASCO#ASCO_CoP#policy#advocacy
📢 Big News from ISLB!
The Journal of Liquid Biopsy is Now Indexed in Scopus 🎉
We’re proud to share that the Journal of Liquid Biopsy — the official journal of the International Society of Liquid Biopsy (ISLB) — has been accepted for indexing on the Scopus platform!
This major milestone highlights the growing impact and credibility of research in liquid biopsy. On behalf of our Editor-in-Chief @UmbertoMalapel1 , @ElsevierConnect , and the editorial board, we extend our deepest thanks to all our authors, reviewers, and readers for making this possible.
🗓️ Articles will be listed on the Scopus Title list by late July/early August, and first citations are expected within 2–3 months.
📚 About the Journal:
@jlb_islb publishes cutting-edge research focused on liquid biopsy-based biomarkers (cfDNA, ctDNA, miRNA, CTCs, EVs, proteins, and more), encouraging an integrated approach across molecular science, technical innovation, and clinical application.
🔗 Learn more: https://t.co/QJTSvdlwjp
#ISLB #LiquidBiopsy #Scopus #OpenAccess #PrecisionOncology #MolecularDiagnostics
@ChristianRolfo@ElJanLe@RobertoBoreaMD@DrYukselUrun@ErulEnes@UmbertoMalapel1@drgandara@MJOSESERRANO19@ReduzziCarol
Every cancer patient deserves a diagnosis
Providing links. as requested.
2016 AMA journal paper:
https://t.co/BkEq2r1YRu
2023 ASCO journal paper
https://t.co/vejItiKryV
@VivekSubbiah
Real-world HER2 testing across 65,000+ solid tumors after T-DXd approval.
🧬Highest HER2 3+ rates:
Bladder 13.9%
Uterine serous 13.6%
GEJ 12.1%
Breast 7.8%
Gastric 6.6%
🧬0% in glioma, sarcoma, SCLC, GIST, thyroid, thymic...
Routine HER2 IHC may not be needed for all tumors.
@JAMAOnc@OncoAlert@OncBrothers@US_FDA@myESMO@ASCO
https://t.co/u4vl2NKLnS
🔥@trendscancer🆙
✅Turning cold into hot: emerging strategies to fire up the tumor microenvironment
🎯Summary of the intrinsic, extrinsic, and systemic factors developing ‘cold’ tumors
👥Dr. Kaili Ma
#LCSM@OncoAlert#ICI
https://t.co/p3IW9hjSOi
Absolutely insane amount of data in this resource from @mason_lab
The Spatial Atlas of Human Anatomy (SAHA): A Multimodal Subcellular-Resolution Reference Across Human Organs
https://t.co/rwKWVtidfZ
Spatial data on 15million cells from 100 donors across multiple ages, mainly GI
Great paper from our ISLB Young Committee!
A huge effort to keep sharing #LiquidBiopsy knowledge through reviews and editorials after major conferences worldwide.
Follow us for more LB updates and insights! 🌍🧬
#ISLB#sciencecommunication